Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a randomised, double-blind, placebo-controlled trial

Lancet · 2021

In a 26-week phase 2 trial, once-weekly cagrilintide 2.4 mg reduced mean body weight by 10.8% compared with 3.0% for placebo in adults with overweight or obesity, with all doses showing dose-dependent weight reduction and a tolerability profile consistent with amylin receptor agonism.

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.

J Diabetes Metab Disord · 2026

# Summary Research found that cagrilintide, both alone and in combination with semaglutide (CagriSema), produced clinically meaningful reductions in body weight compared to placebo in adults with overweight or obesity, with CagriSema additionally demonstrating improvements in waist circumference and blood sugar levels. This study demonstrated that both treatments were associated with acceptable tolerability, supporting their potential role as pharmacologic options for obesity management.

A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.

Nat Metab · 2026

Cellular loci for cagrilintide action identified.

Nat Metab · 2026

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.

Metabol Open · 2026

# Summary Research found that cagrilintide, a long-acting amylin pathway analog, achieves weight reductions up to 24% by activating distinct neuroendocrine circuits independent of GLP-1 receptor mechanisms. This study demonstrated that amylin-based approaches represent an emerging therapeutic strategy in the next generation of obesity pharmacotherapy beyond traditional GLP-1 receptor agonists.

Beyond weight loss: multisystem benefits of obesity medications.

Lancet Diabetes Endocrinol · 2026

A systematic review of RCT and meta-analysis evidence on approved and late-stage obesity medications—including cagrilintide-semaglutide—found multisystem benefits beyond weight loss across type 2 diabetes, cardiovascular disease, metabolic liver disease, obstructive sleep apnoea, and quality of life, with accumulating evidence for weight-independent GLP-1 receptor-mediated mechanisms.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.

Lancet · 2021

Cagrilintide co-administered with semaglutide 2.4 mg once-weekly was well tolerated. Mean body weight reductions of 15.4–17.1% at 20 weeks with the combination versus 8.0–9.8% with semaglutide-matched placebo cohorts. Most adverse events were mild-to-moderate gastrointestinal events; no pharmacokinetic interaction between compounds.